Cormorant Asset Management, LP - Oct 23, 2023 Form 4 Insider Report for Ambrx Biopharma, Inc. (AMAM)

Role
10%+ Owner
Signature
/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner, By: Bihua Chen, Managing Member
Stock symbol
AMAM
Transactions as of
Oct 23, 2023
Transactions value $
$9,139,542
Form type
4
Date filed
10/25/2023, 04:15 PM
Previous filing
Sep 19, 2023
Next filing
Dec 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMAM Common Stock Purchase $9.14M +1.31M +13.17% $6.99 11.2M Oct 23, 2023 See Footnotes F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $6.57 to $7.10 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund (as defined below).
F2 The number of shares of common stock of the issuer reported herein give effect to the automatic conversion of each ordinary share of Ambrx Biopharma Cayman, Inc. (formerly Ambrx Biopharma Inc., the "Predecessor Issuer") into one-seventh of one share of common stock of the Issuer in connection with the merger of the Predecessor Issuer into a wholly-owned subsidiary of the issuer on October 11, 2023, as reported in the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 12, 2023.
F3 Information reported herein relates to shares of common stock owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F4 Represents (i) 8,725,040 shares of common stock beneficially owned by the Master Fund and (ii) 2,505,960 shares of common stock beneficially owned by Fund III.